p.102 抽出テキスト

276. Lee TM, Hsu DT, Kantor P, Towbin JA, Ware SM, Colan SD, et al. Pediatric cardiomyopathies. Circ Res 2017;121:855–873. https://doi.org/10.1161/CIRCRESAHA.116. 309386 277. Chang RR, Allada V. Electrocardiographic and echocardiographic features that distinguish anomalous origin of the left coronary artery from pulmonary artery from idiopathic dilated cardiomyopathy. Pediatr Cardiol 2001;22:3–10. https://doi.org/10.1007/ s002460010142 278. Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. J Am Coll Cardiol 2007;50:1914–1931. https://doi.org/10.1093/eurheartj/ehm456 279. Law YM, Lal AK, Chen S, Cihakova D, Cooper LT Jr, Deshpande S, et al. Diagnosis and management of myocarditis in children: a scientific statement from the American Heart Association. Circulation 2021;144:e123–e135. https://doi.org/10.1161/CIR. 0000000000001001 280. Fatkin D, MacRae C, Sasaki T, Wolff MR, Porcu M, Frenneaux M, et al. Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N Engl J Med 1999;341:1715–1724. https://doi.org/10. 1056/NEJM199912023412302 281. Towbin JA, Hejtmancik JF, Brink P, Gelb B, Zhu XM, Chamberlain JS, et al. X-linked dilated cardiomyopathy. Molecular genetic evidence of linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus. Circulation 1993;87:1854–1865. https://doi.org/10.1161/01.CIR.87.6.1854 282. D’Amario D, Amodeo A, Adorisio R, Tiziano FD, Leone AM, Perri G, et al. A current approach to heart failure in Duchenne muscular dystrophy. Heart 2017;103: 1770–1779. https://doi.org/10.1136/heartjnl-2017-311269 283. Towbin JA. Left ventricular noncompaction: a new form of heart failure. Heart Fail Clin 2010;6:453–469. https://doi.org/10.1016/j.hfc.2010.06.005 284. Towbin JA, Lorts A, Jefferies JL. Left ventricular non-compaction cardiomyopathy. Lancet 2015;386:813–825. https://doi.org/10.1016/S0140-6736(14)61282-4 285. Pignatelli RH, McMahon CJ, Dreyer WJ, Denfield SW, Price J, Belmont JW, et al. Clinical characterization of left ventricular noncompaction in children: a relatively common form of cardiomyopathy. Circulation 2003;108:2672–2678. https://doi.org/10. 1161/01.CIR.0000100664.10777.B8 286. Webber SA, Lipshultz SE, Sleeper LA, Lu M, Wilkinson JD, Addonizio LJ, et al. Outcomes of restrictive cardiomyopathy in childhood and the influence of phenotype: a report from the Pediatric Cardiomyopathy Registry. Circulation 2012;126: 1237–1244. https://doi.org/10.1161/CIRCULATIONAHA.112.104638 287. Pinto JR, Parvatiyar MS, Jones MA, Liang J, Potter JD. A troponin T mutation that causes infantile restrictive cardiomyopathy increases Ca2+ sensitivity of force development and impairs the inhibitory properties of troponin. J Biol Chem 2008;283:2156–2166. https://doi.org/10.1074/jbc.M707066200 288. Peled Y, Gramlich M, Yoskovitz G, Feinberg MS, Afek A, Polak-Charcon S, et al. Titin mutation in familial restrictive cardiomyopathy. Int J Cardiol 2014;171:24–30. https:// doi.org/10.1016/j.ijcard.2013.11.037 289. Mogensen J, Kubo T, Duque M, Uribe W, Shaw A, Murphy R, et al. Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. J Clin Invest 2003;111:209–216. https://doi.org/10.1172/JCI200316336 290. Protonotarios N, Tsatsopoulou A. Naxos disease and Carvajal syndrome: cardiocutaneous disorders that highlight the pathogenesis and broaden the spectrum of arrhythmogenic right ventricular cardiomyopathy. Cardiovasc Pathol 2004;13:185–194. https:// doi.org/10.1016/j.carpath.2004.03.609 291. McKoy G, Protonotarios N, Crosby A, Tsatsopoulou A, Anastasakis A, Coonar A, et al. Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease). Lancet 2000; 355:2119–2124. https://doi.org/10.1016/S0140-6736(00)02379-5 292. Carvajal-Huerta L. Epidermolytic palmoplantar keratoderma with woolly hair and dilated cardiomyopathy. J Am Acad Dermatol 1998;39:418–421. https://doi.org/10.1016/ S0190-9622(98)70317-2 293. Smedsrud MK, Chivulescu M, Forsa MI, Castrini I, Aabel EW, Rootwelt-Norberg C, et al. Highly malignant disease in childhood-onset arrhythmogenic right ventricular cardiomyopathy. Eur Heart J 2022;43:4694–4703. https://doi.org/10.1093/eurheartj/ ehac485 294. Kontorovich AR, Patel N, Moscati A, Richter F, Peter I, Purevjav E, et al. Myopathic cardiac genotypes increase risk for myocarditis. JACC Basic Transl Sci 2021;6:584–592. https://doi.org/10.1016/j.jacbts.2021.06.001 295. Poller W, Haas J, Klingel K, Kuhnisch J, Gast M, Kaya Z, et al. Familial recurrent myocarditis triggered by exercise in patients with a truncating variant of the desmoplakin gene. J Am Heart Assoc 2020;9:e015289. https://doi.org/10.1161/JAHA.119.015289 296. Martins D, Ovaert C, Khraiche D, Boddaert N, Bonnet D, Raimondi F. Myocardial inflammation detected by cardiac MRI in arrhythmogenic right ventricular cardiomyopathy: a paediatric case series. Int J Cardiol 2018;271:81–86. https://doi.org/10.1016/j. ijcard.2018.05.116 297. Bariani R, Cipriani A, Rizzo S, Celeghin R, Bueno Marinas M, Giorgi B, et al. ‘Hot phase’ clinical presentation in arrhythmogenic cardiomyopathy. Europace 2021;23:907–917. https://doi.org/10.1093/europace/euaa343 298. Ross RD. The Ross classification for heart failure in children after 25 years: a review and an age-stratified revision. Pediatr Cardiol 2012;33:1295–1300. https://doi.org/10. 1007/s00246-012-0306-8 299. Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J 2022;43:3997–4126. https://doi. org/10.1093/eurheartj/ehac262 300. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020;41:407–477. https://doi.org/10.1093/eurheartj/ehz425 301. Brignole M, Moya A, de Lange FJ, Deharo JC, Elliott PM, Fanciulli A, et al. 2018 ESC Guidelines for the diagnosis and management of syncope. Eur Heart J 2018; 39: 1883–1948. https://doi.org/10.1093/eurheartj/ehy037 302. Ahmad F, Seidman JG, Seidman CE. The genetic basis for cardiac remodeling. Annu Rev Genomics Hum Genet 2005;6:185–216. https://doi.org/10.1146/annurev.genom.6. 080604.162132 303. Ferro MD, Stolfo D, Altinier A, Gigli M, Perrieri M, Ramani F, et al. Association between mutation status and left ventricular reverse remodelling in dilated cardiomyopathy. Heart 2017;103:1704–1710. https://doi.org/10.1136/heartjnl-2016-311017 304. de Boer RA, Heymans S, Backs J, Carrier L, Coats AJS, Dimmeler S, et al. Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC). Eur J Heart Fail 2022;24:406–420. 305. Oghina S, Bougouin W, Bezard M, Kharoubi M, Komajda M, Cohen-Solal A, et al. The impact of patients with cardiac amyloidosis in HFpEF trials. JACC Heart Fail 2021;9: 169–178. https://doi.org/10.1016/j.jchf.2020.12.005 306. Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid M, Adamopoulos S, Albert N, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. J Card Fail 2021;3:S1071-9164(21)00050-6. https://doi. org/10.1016/j.cardfail.2021.01.022 307. Halliday BP, Wassall R, Lota AS, Khalique Z, Gregson J, Newsome S, et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet 2019;393: 61–73. https://doi.org/10.1016/S0140-6736(18)32484-X 308. Mureddu GF, Tarantini L, Agabiti N, Faggiano P, Masson S, Latini R, et al. Evaluation of different strategies for identifying asymptomatic left ventricular dysfunction and preclinical (stage B) heart failure in the elderly. Results from ‘PREDICTOR’, a population based-study in central Italy. Eur J Heart Fail 2013;15:1102–1112. https://doi.org/10. 1093/eurjhf/hft098 309. Green EM, Wakimoto H, Anderson RL, Evanchik MJ, Gorham JM, Harrison BC, et al. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science 2016;351:617–621. https://doi.org/10.1126/science. aad3456 310. Masarone D, Valente F, Rubino M, Vastarella R, Gravino R, Rea A, et al. Pediatric heart failure: a practical guide to diagnosis and management. Pediatr Neonatol 2017;58: 303–312. https://doi.org/10.1016/j.pedneo.2017.01.001 311. Loss KL, Shaddy RE, Kantor PF. Recent and upcoming drug therapies for pediatric heart failure. Front Pediatr 2021;9:681224. https://doi.org/10.3389/fped.2021.681224 312. Arya A, Azad S, Sitaraman R. Angiotensin receptor and neprylisin inhibitor: a new drug in pediatric cardiologist’s armamentarium. Ann Pediatr Cardiol 2020;13:334–336. https://doi.org/10.4103/apc.APC_9_20 313. Biagini E, Spirito P, Leone O, Picchio FM, Coccolo F, Ragni L, et al. Heart transplantation in hypertrophic cardiomyopathy. Am J Cardiol 2008;101:387–392. https://doi. org/10.1016/j.amjcard.2007.09.085 314. Bograd AJ, Mital S, Schwarzenberger JC, Mosca RS, Quaegebeur JM, Addonizio LJ, et al. Twenty-year experience with heart transplantation for infants and children with restrictive cardiomyopathy: 1986–2006. Am J Transplant 2008;8:201–207. https://doi. org/10.1111/j.1600-6143.2007.02027.x 315. Marstrand P, Han L, Day SM, Olivotto I, Ashley EA, Michels M, et al. Hypertrophic cardiomyopathy with left ventricular systolic dysfunction: insights from the SHaRe registry. Circulation 2020;141:1371–1383. https://doi.org/10.1161/CIRCULATIONAHA. 119.044366 316. DePasquale EC, Nasir K, Jacoby DL. Outcomes of adults with restrictive cardiomyopathy after heart transplantation. J Heart Lung Transplant 2012;31:1269–1275. https:// doi.org/10.1016/j.healun.2012.09.018 317. Khush KK, Cherikh WS, Chambers DC, Harhay MO, Hayes D Jr, Hsich E, et al. The international thoracic organ transplant registry of the International Society for Heart and Lung Transplantation: thirty-sixth adult heart transplantation report – 2019; focus theme: donor and recipient size match. J Heart Lung Transplant 2019;38: 1056–1066. https://doi.org/10.1016/j.healun.2019.08.004 Downloaded from academic.oup.com/eurheartj/article/44/37/3503/7246608 by guest on 07 October 2026